Rethinking Insulin Resistance in Aging: A Reserve-Oriented Clinical Framework (Paper July 2026)

Key Takeaways

• Canagliflozin 100‑300 mg daily mimics caloric restriction, extends mouse lifespan 14%
• Fisetin intermittent high‑dose clears senescent cells, improves grip strength
• Intranasal insulin 40 IU/day protects brain white matter without hypoglycemia
• Nicotinamide riboside 1 g daily boosts muscle NAD+ and reduces inflammation
• Semaglutide weekly 1‑2.4 mg lowers inflammaging, enhances mitochondrial function

Pulse Analysis

The reserve‑oriented model shifts the therapeutic focus from body mass to the quality of metabolic substrates, especially skeletal muscle. In older adults, myosteatosis and mitochondrial decay drive insulin resistance more than excess adiposity, making interventions that enhance muscle oxidative capacity—such as progressive resistance training and high‑protein nutrition—central to any longevity strategy. This perspective aligns with emerging data that pharmacologic agents can act as metabolic mimetics, amplifying the benefits of exercise and diet.

SGLT2 inhibitors like canagliflozin and empagliflozin now appear as calorie‑restriction mimetics, triggering AMPK activation and mTOR suppression while promoting fatty‑acid oxidation. Preclinical mouse work demonstrates a 14% median lifespan gain, and human dosing (100‑300 mg daily) is well tolerated with manageable risks of genitourinary infections and volume depletion. When paired with resistance training and protein supplementation, these agents can counteract the lean‑mass loss often seen with weight‑loss drugs in frail elders.

Beyond glucose‑lowering, the paper highlights a suite of complementary therapies: intermittent high‑dose fisetin removes senescent adipocytes, intranasal insulin delivers neuroprotective effects without systemic hypoglycemia, and nicotinamide riboside replenishes NAD+ pools to revive sirtuin‑driven mitochondrial function. Weekly semaglutide adds anti‑inflammaging benefits via AMPK/SIRT1 pathways. Together, these modalities form a synergistic “longevity stack” that addresses both peripheral and central insulin resistance, offering a pragmatic roadmap for clinicians aiming to extend healthspan in the aging population.